NVCR · XBRL financial data

NovoCure financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NVCR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	494	535	538	509	605	655
Cost of revenue	107	115	115	128	137	167
Gross profit	388	420	423	381	468	488
Research and development	132	201	206	223	210	225
General and administrative	107	126	133	164	190	178
Total operating expenses	357	464	512	614	639	642
Operating income (loss)	30	(44)	(90)	(233)	(170)	(154)
Interest income	2	1	11	20	23	13
Interest expense	18	9	8	5	12	22
Income tax expense (benefit)	(2)	6	11	15	37	(0)
Net income (loss)	20	(58)	(93)	(207)	(169)	(136)
Earnings per share, basic USD per share	0.20	(0.56)	(0.88)	(1.95)	(1.56)	(1.22)
Earnings per share, diluted USD per share	0.18	(0.56)	(0.88)	(1.95)	(1.56)	(1.22)
Weighted average shares, basic millions of shares	101	103	105	106	108	111
Weighted average shares, diluted millions of shares	109	103	105	106	108	111

Fiscal years (NVCR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	235	209	115	241	164	94
Accounts receivable	97	94	86	61	74	89
Inventory	27	24	29	38	35	41
Total current assets	999	1,074	1,112	1,034	1,107	647
Property and equipment, net	11	23	33	51	78	78
Right-of-use asset	19	18	24	35	27	47
Total assets	1,052	1,139	1,192	1,146	1,241	804
Current portion of long-term debt	—	—	—	—	—	0
Total current liabilities	114	143	159	179	756	223
Long-term debt	430	562	566	569	97	195
Lease liability, non-current	14	13	19	27	20	42
Total liabilities	575	729	750	784	881	464
Accumulated deficit	(631)	(686)	(778)	(986)	(1,154)	(1,290)
Total stockholders' equity	477	410	441	362	360	340
Total liabilities and equity	1,052	1,139	1,192	1,146	1,241	804
Common shares outstanding (cover page) millions of shares	102	104	105	107	110	114

Fiscal years (NVCR's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	20	(58)	(93)	(207)	(169)	(136)
Stock-based compensation	76	95	107	116	160	105
Net cash from operating activities	99	83	31	(73)	(26)	(49)
Purchases of property and equipment	15	24	21	27	43	27
Net cash from investing activities	(473)	(145)	(140)	184	(140)	437
Proceeds from issuing common stock	3	5	5	4	4	4
Proceeds from long-term debt	558	—	0	0	97	100
Repayments of long-term debt	150	0	0	0	13	561
Net cash from financing activities	440	26	15	16	90	(451)
Net change in cash	67	(37)	(94)	127	(76)	(63)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
NovoCure	97	193	23	116.9M	—	Q3 FY26 10-QSep 30, 2026
Establishment Labs Holdings	71	68	(17)*	29.8M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Integra Lifesciences Holdings	252	411	96*	77.8M	—	Q3 FY26 10-QSep 30, 2026
Biolife Solutions	24	not reported	6.3*	48.9M	—	Q2 FY26 10-QJun 30, 2026
CONMED	48	336	49*	29.8M	—	Q3 FY26 10-QSep 30, 2026
SI-BONE	35	56	5.9*	45.1M	—	Q3 FY26 10-QSep 30, 2026
Alphatec Holdings	80	221	19*	155.1M	—	Q3 FY26 10-QSep 30, 2026
Tandem Diabetes Care	63	255	(35)*	69.6M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Embecta	215	272	42*	56.7M	—	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.